评估从分化 20 (CD20) 抗簇治疗过渡到 Ublituximab 时疗效维持的研究 (ENHANCE)
从抗 CD20 治疗过渡到 Ublituximab 时评估疗效的维持
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:TG Therapeutics Clinical Support Team
- 电话号码:1-877-575-8489
- 邮箱:clinicalsupport@tgtxinc.com
学习地点
-
-
-
Bydgoszcz、波兰、85-796
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Katowice、波兰、40-555
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Kielce、波兰、25-726
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Krakow、波兰、31-826
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Lodz、波兰、90-324
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Olsztyn、波兰、10-561
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Poznan、波兰、61-583
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Warsaw、波兰、04-141
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Zabrze、波兰
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Żory、波兰、44-240
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35209
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Cullman、Alabama、美国、35058
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
California
-
Orange、California、美国、92697
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Colorado
-
Fort Collins、Colorado、美国、80528
- 招聘中
- TG Investigational Site
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20007
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Florida
-
Tampa、Florida、美国、33612
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Georgia
-
Atlanta、Georgia、美国、30309
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Atlanta、Georgia、美国、30322
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Savannah、Georgia、美国、31406
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Illinois
-
Chicago、Illinois、美国、60612
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Indiana
-
Indianapolis、Indiana、美国、46256
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Kansas
-
Overland Park、Kansas、美国、66212
- 完全的
- TG Therapeutics Investigational Trial Site
-
Overland Park、Kansas、美国、66205
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Maryland
-
Lutherville、Maryland、美国、21093
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Massachusetts
-
Boston、Massachusetts、美国、70809
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Boston、Massachusetts、美国、00002
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Foxborough、Massachusetts、美国、02035
- 招聘中
- TG Therapeutics Investigational Trial Site
-
North Worcester、Massachusetts、美国、01655
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Wellesley、Massachusetts、美国、02481
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Michigan
-
Farmington、Michigan、美国、48334
- 招聘中
- TG Investigational Site
-
-
Minnesota
-
Golden Valley、Minnesota、美国、55422
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Plymouth、Minnesota、美国、55446
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Missouri
-
St Louis、Missouri、美国、63131
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
New York
-
New York、New York、美国、10025
- 招聘中
- TG Therapeutics Investigational Trial Site
-
New York、New York、美国、11021
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
North Carolina
-
Charlotte、North Carolina、美国、28204
- 招聘中
- TG Therapeutics Investigational Trial SiteCharlotte
-
Raleigh、North Carolina、美国、27607
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Ohio
-
Cincinnati、Ohio、美国、45212
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Cleveland、Ohio、美国、44195
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Dayton、Ohio、美国、45417
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
South Carolina
-
Greenville、South Carolina、美国、29605
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Tennessee
-
Knoxville、Tennessee、美国、37922
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Texas
-
Houston、Texas、美国、77030
- 完全的
- TG Therapeutics Investigational Trial Site
-
-
Utah
-
Salt Lake City、Utah、美国、84103
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Virginia
-
Vienna、Virginia、美国、22182
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Washington
-
Kirkland、Washington、美国、98034
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Seattle、Washington、美国、98109
- 招聘中
- TG Therapeutics Investigational Trial Site
-
Spokane、Washington、美国、99208
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- 招聘中
- TG Therapeutics Investigational Trial Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Diagnosis of RMS (2017 Revised McDonald criteria).
-
Participants must meet one of the following prior treatment definitions:
- Participants naïve to treatment.
- Participants previously treated with a disease modifying therapy (DMT) who have discontinued treatment prior to consent and meet the washout requirements.
-
Expanded Disability Status Scale (EDSS) score ≤ 5.5 at screening.
-
Neurologically stable for > 30 days prior to first dose of ublituximab.
-
Female participants of childbearing potential must consent to use a medically acceptable method of contraception from consent, throughout the study period, and for 6 months after the last dose of ublituximab.
-
Part C: participants currently treated with an anti-CD20 agent for at least 6 months and meet the washout requirements prior to W1D1.
-
Part C: Discontinuation of current anti-CD20 must be due to suboptimal experience
Exclusion Criteria:
- History of any serious 3 Infusion Related Reaction (IRR) on prior anti-CD20 therapy.
- Primary-progressive multiple sclerosis (PPMS) or inactive Secondary Progressive MS (SPMS).
- Active chronic (or stable but treated with immune therapy) disease of the immune system other than MS (e.g., rheumatoid arthritis, scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or immunodeficiency syndrome (hereditary immune deficiency, drug-induced immune deficiency, etc.).
- Current evidence or known history of clinically significant infection, including: chronic, recurrent, or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment such as, but not limited to chronic urinary tract infection, chronic pulmonary infection with bronchiectasis, tuberculosis, or active hepatitis C virus (HCV).
- Previous serious opportunistic or atypical infection.
- Evidence of chronic active or history of hepatitis B virus (HBV) infection as evidenced by a detectable hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb), or chronic hepatitis C infection. Participants with positive hepatitis C virus antibody (HCV Ab) are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).
- History or evidence (clinical, radiological, or biomarker) of suspected or confirmed progressive multifocal leukoencephalopathy (PML).
- Receipt of any live or live-attenuated vaccines (including vaccines for varicella-zoster virus or measles) within 4 weeks prior to first study drug administration.
- Participants requiring treatment with intravenous immune globulin (IVIG) for decreased immunoglobulins within the 12 months prior to W1D1.
- Any active malignancies other than adequately treated basal, squamous cell or in situ carcinoma.
- Participants who have ever received ublituximab, alemtuzumab, cyclophosphamide, mitoxantrone, cladribine, or daclizumab (including for non-MS indications).
Note: Other Inclusion/Exclusion criteria may apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part A: Ublituximab
Participants will receive a modified regimen of ublituximab including infusions on Day 1 of Week 1 (W1D1), Day 15, if applicable, and ublituximab 450 milligrams (mg) infusion at Week 24. With Protocol Version 6.0, enrollment in Part A was closed. |
Administered as an intravenous (IV) infusion.
其他名称:
|
|
实验性的:Part B: Ublituximab /Placebo (Treatment Arm A)
Participants will receive 600 mg of ublituximab on W1D1 followed by a placebo infusion on Day 15 and 450 mg ublituximab infusion at Week 24. With Protocol Version 7.0, enrollment in Part B will be closed. |
IV infusion Administered as an intravenous (IV) infusion.
其他名称:
|
|
实验性的:Part B: Ublituximab (Treatment Arm B)
Participants will receive 150 mg of ublituximab on W1D1 followed by 450 mg on Day 15 and at Week 24. With Protocol Version 7.0, enrollment in Part B will be closed. |
Administered as an intravenous (IV) infusion.
其他名称:
|
|
实验性的:Part C: Ublituximab (Treatment Arm C)
Participants will receive 150 mg of ublituximab on W1D1, followed by 450 mg on Day 15 and at Week 24. |
Administered as an intravenous (IV) infusion.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Part B:ublituximab 治疗前 16 周曲线下面积(AUC0-W16)
大体时间:给药前及至第16周的多个时间点
|
给药前及至第16周的多个时间点
|
|
|
Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48
大体时间:Baseline up to Week 48
|
The Gd-enhancing T1 lesions will be evaluated using magnetic resonance imaging (MRI) technique. |
Baseline up to Week 48
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Parts A: Percentage of Participants Free of T1 Gd-Enhancing Lesions
大体时间:Week 48
|
The Gd-enhancing T1 lesions will be evaluated using MRI technique. |
Week 48
|
|
Parts A and B: Percentage of Participants Experiencing Infusion Related Reactions (IRRs)
大体时间:Up to Week 48
|
IRRs are defined as infusion related adverse events (AEs) that occur within one day of an infusion and resolve within 7 days. IRRs will be reported by investigator. |
Up to Week 48
|
|
Parts A: Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores
大体时间:Part A: Baseline, Week 24 and Week 48
|
The TSQM-9 is a 9-item questionnaire with 3 domains: Satisfaction, convenience, and effectiveness. |
Part A: Baseline, Week 24 and Week 48
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- TG1101-RMS401
- 2024-519284-18-00 (其他标识符:EU CT Number)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.